The FDA has expanded emergency authorization of Covid-19 boosters to include children 12 to 15 vaccinated with the Pfizer and BioNTech messenger RNA shot. The decision is based on a study that found boosting reduced deaths by 90%, but that Israeli analysis only evaluated these shots in people 50 and older.
At a time when a large portion of healthcare practitioner interactions have switched to digital, it's clear that life science companies need to transform their approach to be much more collaborative in the way they work with healthcare professionals.
A new survey from Reuters Events in collaboration with Microsoft and Exeevo, Medical-commercial collaborating to win in the digital era, offers an inside look at the trends and challenges with which life science professionals have to contend, and how they are responding and explores new strategies and tactics for how these companies are working with healthcare providers and adapting themselves to improve the patient experience in healthcare.
INVEST 2022 is going to be held March 28-30 in at the Ritz Carlton hotel in Chicago. This year, we have four new categories reflecting the pandemic-reality and how it has reshaped healthcare. Apply now for a chance to pitch LIVE in front of VC judges. Please note that companies that have pitched in the last 12 months at a MedCity event are ineligible to apply. Selected finalists will be asked to register for the conference at a reduced rate.
By Stephanie Baum Tuesday, January 4, 2022 7:30 AM
"Most Q&As are happening on Twitter. If you're not doing social listening you're losing fresh insights into things like disease states." That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.
Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda Pharmaceutical paid $196 million up front to acquire Ovid's rights to a Phase 3 ready molecule for two rare forms of epilepsy.
By Catherine Freeland Monday, January 3, 2022 8:15 AM
For many health researchers, when it comes to engaging with specific audiences, you don't know what you don't know. Don't assume you understand your target audiences. Don't use your language to engage with them. Connect with them. Learn from them.
No comments